One of the first places many people show weight gain is in the face-especially in the form of an unflattering double chin. For that reason, we imagine there will be no shortage of patients willing to try a new injectable drug made to combat exactly this area of frustrating fat.
Pharmaceutical big shot Bayer has announced that they will be conducting trials for ATX-101, an adipolytic agent used to reduce fat under the chin, with the goal of eventually offering “a well-studied, clinically-proven treatment to reduce localized submental fat without surgery,” according to a recent statement.
A Bayer spokesperson likens the treatment to getting a tattoo. Instead of a single injection in a single appointment, ATX-101 would be administered with approximately 50 tiny injections into the fat cells over the course of several sessions. Results are reportedly noticeable in about 16 weeks.
“There is a huge demand for a safe, effective and approved injectable treatment for localized fat reduction,” said French dermatologist and ATX-101 researcher Jean-Paul Ortonne; and arguably, Americans would be no exception to that interest.
However, at this time, Bayer expects to market the new injectable in 2014 within Europe, Asia and South America-no mention of their US intentions.
Would you be interested in ATX-101 if was eventually approved by the FDA? Why or why not? Leave a comment below!
Find a Doctor
Find a NewBeauty "Top Beauty Doctor" Near you